Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sanofi SA (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SNY
Nasdaq
2834
https://www.sanofi.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sanofi SA (ADR)
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
- Mar 28th, 2024 3:30 pm
32 Countries with the Highest Rates of Diabetes
- Mar 26th, 2024 9:10 am
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
- Mar 22nd, 2024 3:33 pm
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
- Mar 22nd, 2024 6:30 am
Mirador Therapeutics raises over $400 mln in early funding rounds
- Mar 21st, 2024 11:00 am
Sanofi: Information concerning the total number of voting rights and shares - February 2024
- Mar 15th, 2024 7:04 pm
PE Firms Eye €7.5 Billion Buyout Financing for Sanofi Unit
- Mar 15th, 2024 5:03 pm
12 Most Profitable Biotech Stocks To Invest In
- Mar 14th, 2024 1:38 pm
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
- Mar 12th, 2024 1:58 pm
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
- Mar 11th, 2024 6:00 am
UPDATE 2-Astra-Sanofi's RSV therapy 90% effective against infant hospitalizations, CDC study shows
- Mar 7th, 2024 7:15 pm
13 Best Pharma Dividend Stocks To Buy in 2024
- Mar 5th, 2024 7:56 am
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
- Feb 29th, 2024 1:50 pm
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
- Feb 28th, 2024 1:08 pm
3 Cash Cow Dividend Stocks for Outsized Income & Upside
- Feb 27th, 2024 10:51 pm
Denali, fresh off study setback, gets $500M lift
- Feb 27th, 2024 11:53 am
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
- Feb 24th, 2024 2:51 pm
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
- Feb 23rd, 2024 5:45 pm
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript
- Feb 23rd, 2024 4:59 pm
20 Fastest Growing Biotech Companies in the US
- Feb 23rd, 2024 10:43 am
Scroll